Biological response genes after single dose administration of interferon β-1b to healthy male volunteers

[1]  B. Williams,et al.  Novel interferon‐β‐induced gene expression in peripheral blood cells , 2007, Journal of leukocyte biology.

[2]  Ludwig Kappos,et al.  Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study , 2007, The Lancet.

[3]  E. Waubant,et al.  Identification of short-term pharmacodynamic effects of interferon-beta-1a in multiple sclerosis subjects with broad- based phenotypic profiling , 2007, Journal of Neuroimmunology.

[4]  W. A. LaFramboise,et al.  Gene expression changes in peripheral blood mononuclear cells from multiple sclerosis patients undergoing β-interferon therapy , 2007, Journal of the Neurological Sciences.

[5]  J. Justesen,et al.  The human 2'-5'oligoadenylate synthetase family: unique interferon-inducible enzymes catalyzing 2'-5' instead of 3'-5' phosphodiester bond formation. , 2007, Biochimie.

[6]  G. Salvesen,et al.  The apoptosome: signalling platform of cell death , 2007, Nature Reviews Molecular Cell Biology.

[7]  Parvin Mousavi,et al.  Genome-Wide Network Analysis Reveals the Global Properties of IFN-β Immediate Transcriptional Effects in Humans12 , 2007, The Journal of Immunology.

[8]  L. Kappos,et al.  Pharmacodynamics of interferon beta in multiple sclerosis patients with or without serum neutralizing antibodies , 2007, Journal of Neurology.

[9]  C. Scagnolari,et al.  Expression of biomarkers of interferon type I in patients suffering from chronic diseases , 2007, Clinical and experimental immunology.

[10]  P. Kloetzel,et al.  Virus-induced type I IFN stimulates generation of immunoproteasomes at the site of infection. , 2006, The Journal of clinical investigation.

[11]  J. De Keyser,et al.  Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes , 2006, Neurology.

[12]  R. Ransohoff,et al.  Determinants of CCL5-driven mononuclear cell migration across the blood–brain barrier. Implications for therapeutically modulating neuroinflammation , 2006, Journal of Neuroimmunology.

[13]  M. Wolman,et al.  Repulsion or adhesion: receptors make the call. , 2006, Current opinion in cell biology.

[14]  M. Ramanathan,et al.  Dynamics of interferon-β modulated mRNA biomarkers in multiple sclerosis patients with anti-interferon-β neutralizing antibodies , 2006, Journal of Neuroimmunology.

[15]  A. Takaoka,et al.  Interferon signalling network in innate defence , 2006, Cellular microbiology.

[16]  Takashi Yamamura,et al.  Microarray analysis identifies a set of CXCR3 and CCR2 ligand chemokines as early IFNβ-responsive genes in peripheral blood lymphocytes in vitro: an implication for IFNβ-related adverse effects in multiple sclerosis , 2006, BMC neurology.

[17]  Arthur Weiss,et al.  Function of the Src-family kinases, Lck and Fyn, in T-cell development and activation , 2004, Oncogene.

[18]  A. Rivett,et al.  Proteasome function in antigen presentation: immunoproteasome complexes, Peptide production, and interactions with viral proteins. , 2004, Current protein & peptide science.

[19]  F. Bagnato,et al.  Beta-2 microglobulin and neopterin as markers of disease activity in multiple sclerosis , 2003, Neurological Sciences.

[20]  A. Bertolotto,et al.  Measurement of MxA mRNA or protein as a biomarker of IFNβ bioactivity , 2003, Neurology.

[21]  D. Ryglewicz,et al.  Factors predicting early stroke fatality in Poland. Preliminary report of the Polish National Stroke Registry , 2003, Neurological Sciences.

[22]  Murali Ramanathan,et al.  Genomic Effects of IFN-β in Multiple Sclerosis Patients 1 , 2003, The Journal of Immunology.

[23]  R. Mayeux,et al.  Parkinsonian signs in older people , 2003, Neurology.

[24]  D. Fuchs,et al.  Potential role of immune system activation-associated production of neopterin derivatives in humans , 2003, Inflammation Research.

[25]  J. Hidalgo,et al.  Retracted: Treatment with metallothionein prevents demyelination and axonal damage and increases oligodendrocyte precursors and tissue repair during experimental autoimmune encephalomyelitis , 2003, Journal of neuroscience research.

[26]  L. Staudt,et al.  Expression profiling identifies responder and non-responder phenotypes to interferon-beta in multiple sclerosis. , 2003, Brain : a journal of neurology.

[27]  Wei-Min Liu,et al.  Analysis of high density expression microarrays with signed-rank call algorithms , 2002, Bioinform..

[28]  Uwe Oelmueller,et al.  Stabilization of mRNA expression in whole blood samples. , 2002, Clinical chemistry.

[29]  B. Weir,et al.  A systematic statistical linear modeling approach to oligonucleotide array experiments. , 2002, Mathematical biosciences.

[30]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[31]  X. Montalban,et al.  Altered inflammatory response and increased neurodegeneration in metallothionein I+II deficient mice during experimental autoimmune encephalomyelitis , 2001, Journal of Neuroimmunology.

[32]  L. Staudt,et al.  Complex immunomodulatory effects of interferon‐β in multiple sclerosis include the upregulation of T helper 1‐associated marker genes , 2001, Annals of neurology.

[33]  V. Appay,et al.  RANTES: a versatile and controversial chemokine. , 2001, Trends in immunology.

[34]  P. Tan,et al.  Metallothionein 1E mRNA is highly expressed in oestrogen receptor-negative human invasive ductal breast cancer , 2000, British Journal of Cancer.

[35]  M. Reindl,et al.  A comparative study of the relative bioavailability of different interferon beta preparations , 2000, Neurology.

[36]  R. Maibauer,et al.  Pharmacodynamic comparison of single doses of IFN-beta1a and IFN-beta1b in healthy volunteers. , 1999, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[37]  G. Williams,et al.  Comparative study of the pharmacodynamic and pharmacologic effects of Betaseron and AVONEX. , 1998, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[38]  P. Salmon,et al.  Pharmacokinetics and pharmacodynamics of recombinant human interferon-beta in healthy male volunteers. , 1996, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[39]  R. Littell.  SAS System for Mixed Models , 1996 .

[40]  B. Storer,et al.  Pharmacodynamics of biological response in vivo after single and multiple doses of interferon-beta. , 1993, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[41]  T. Schall.  Biology of the RANTES/SIS cytokine family. , 1991, Cytokine.

[42]  M. Aebi,et al.  cDNA structures and regulation of two interferon-induced human Mx proteins , 1989, Molecular and cellular biology.

[43]  R. Chung,et al.  Metallothioneins I and II: neuroprotective significance during CNS pathology. , 2007, The international journal of biochemistry & cell biology.

[44]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .